A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ClinicalTrials.gov ID: NCT00391729

Public ClinicalTrials.gov record NCT00391729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

Study identification

NCT ID: NCT00391729
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Abbott; Industry
Enrollment: 221 participants

Conditions and interventions

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

ABT-089 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2006 (Type not available)
Primary completion: Jun 2007 (Actual)
Completion: Jun 2007 (Actual)
Last update posted: Oct 18, 2011

2006 – 2007

United States locations

U.S. sites: 23
U.S. states: 17
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Mesa	Arizona	85210	—
Not listed	Lafayette	California	94549	—
Not listed	Oceanside	California	92056	—
Not listed	San Diego	California	92103	—
Not listed	Denver	Colorado	80212	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Maitland	Florida	32751	—
Not listed	Miami	Florida	33173	—
Not listed	Tampa	Florida	33606	—
Not listed	Newton	Kansas	67114	—
Not listed	Farmington Hills	Michigan	48336	—
Not listed	Omaha	Nebraska	68198	—
Not listed	Bridgewater	New Jersey	10312	—
Not listed	New York	New York	10010	—
Not listed	Staten Island	New York	10312	—
Not listed	Chapel Hill	North Carolina	27514	—
Not listed	Lyndhurst	Ohio	44124	—
Not listed	Portland	Oregon	97210	—
Not listed	Charleston	South Carolina	29405	—
Not listed	Memphis	Tennessee	38119	—
Not listed	Lake Jackson	Texas	77566	—
Not listed	Herndon	Virginia	20170	—
Not listed	Middleton	Wisconsin	53562	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00391729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 18, 2011 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00391729 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →